Development of Synthesis Technology and Quality Control for the Immunotropic Agent Kemantane


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

A new technology for synthesis of the immunomodulator drug Kemantane was developed.

About the authors

N. I. Avdyunina

V. V. Zakusov Science Research Institute of Pharmacology

Email: chem@folium.ru
Russian Federation, 8 Baltiiskaya Street, Moscow, 125315

A. V. Tolkacheva

V. V. Zakusov Science Research Institute of Pharmacology; I. M. Sechenov First Moscow State Medical University

Email: chem@folium.ru
Russian Federation, 8 Baltiiskaya Street, Moscow, 125315; Building 8, 2 Trubetskaya Street, Moscow, 119991

L. N. Grushevskaya

V. V. Zakusov Science Research Institute of Pharmacology

Email: chem@folium.ru
Russian Federation, 8 Baltiiskaya Street, Moscow, 125315

B. M. Pyatin

V. V. Zakusov Science Research Institute of Pharmacology

Email: chem@folium.ru
Russian Federation, 8 Baltiiskaya Street, Moscow, 125315

R. F. Bol’shakova

V. V. Zakusov Science Research Institute of Pharmacology

Email: chem@folium.ru
Russian Federation, 8 Baltiiskaya Street, Moscow, 125315

N. M. Zaitseva

V. V. Zakusov Science Research Institute of Pharmacology

Email: chem@folium.ru
Russian Federation, 8 Baltiiskaya Street, Moscow, 125315

M. I. Ustinova

V. V. Zakusov Science Research Institute of Pharmacology

Email: chem@folium.ru
Russian Federation, 8 Baltiiskaya Street, Moscow, 125315

V. I. Prokof’eva

I. M. Sechenov First Moscow State Medical University

Email: chem@folium.ru
Russian Federation, Building 8, 2 Trubetskaya Street, Moscow, 119991

L. M. Gaevaya

V. V. Zakusov Science Research Institute of Pharmacology

Email: chem@folium.ru
Russian Federation, 8 Baltiiskaya Street, Moscow, 125315


Copyright (c) 2016 Springer Science+Business Media New York

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies